A comparison of overall survival and quality of life in MDS patients treated with Azacytidine vs Decitabine
James T. England, Liying Zhang, Karen Yee, Michelle Geddes et autres
0 citationsBlood Neoplasia
Robert Delage
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
116Publications signalées
1734Citations signalées
3Affiliations récentes
Institutions déclarées
Domaines associés
Acute Myeloid Leukemia ResearchChronic Lymphocytic Leukemia ResearchChronic Myeloid Leukemia TreatmentsMyeloproliferative Neoplasms: Diagnosis and TreatmentEosinophilic Disorders and Syndromes
Publications récentes
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis
Naveen Pemmaraju, Adam J. Mead, Tim C. P. Somervaille, Francesca Palandri et autres
1 citationBlood
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes
L. Gagnon, Andrea Duminuco, Fabio Stagno, Marta Sobas et autres
1 citationLeukemia
A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study
James T. England, Michelle Geddes, Mitchell Sabloff, Grace Christou et autres
0 citationsBlood
Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)
Guillermo Garcia‐Manero, Uwe Platzbecker, Pierre Fenaux, G. Roboz et autres
7 citationsBlood
Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model
Nicholas L.J. Chornenki, Lisa Chodirker, Lee Mozessohn, Signy Chow et autres
0 citationsBlood
POSTER: MDS-1497 Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes
Guillermo Garcia‐Manero, Uwe Platzbecker, Pierre Fenaux, Gail J. Roboz et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
ORAL ABSTRACT: MDS-1497 Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes
Guillermo Garcia‐Manero, Uwe Platzbecker, Pierre Fenaux, Gail J. Roboz et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
MDS-1497: Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes
Guillermo Garcia‐Manero, Uwe Platzbecker, Pierre Fenaux, Gail J. Roboz et autres
14 citationsClinical Lymphoma Myeloma & Leukemia
Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact—a study of 784 patients from the Quebec MPN research group
Alisa Poullet, Lambert Busque, Shireen Sirhan, Robert Delage et autres
5 citationsBlood Cancer Journal
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study
Lambert Busque, Marc-Étienne Beaudet, Michaël Harnois, Hanane Moussa et autres
12 citationsBlood Cancer Journal
Radiotherapeutic Treatment of an Epidermoid Tumor in a Patient With Zanubrutinib-Treated Mantle Cell Lymphoma: The First Report of Concomitant Treatment
François Fabi, Louis-Philippe Grenier, Robert Delage, A. Fortin
0 citationsCureus
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.